Evidence map›Paper›PMID 33903234›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

NMR unveils an N-terminal interaction interface on acetylated-α-synuclein monomers for recruitment to fibrils.

Xue Yang, Baifan Wang, Cody L Hoop, Jonathan K Williams, Jean Baum

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. The amplification of α-synuclein amyloid fibrils.Biochemical Society transactions · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. ZnJournal of the American Chemical Society · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Residues 2 to 7 of α-synuclein regulate amyloid formation via lipid-dependent and lipid-independent pathways.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  18. Article
  19. Structural Insights into Seeding Mechanisms of hIAPP Fibril Formation.Journal of the American Chemical Society · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Xue YangDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854.
Baifan WangDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854.
Cody L HoopDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854.ORCID 0000-0003-4441-8321
Jonathan K WilliamsDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854.ORCID 0000-0002-7272-6885
Jean BaumDepartment of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ 08854 jean.baum@rutgers.edu.
Rutgers, The State University of New Jersey · US

Funding

Rutgers Helium Recovery System for High Field NMRR35GM136431 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI BAUM, JEAN S · 2020 to 2024
$3.3M
NMR Based Studies of Alpha-Synuclein Aggregation and InhibitionR01GM110577 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI BAUM, JEAN S · 2015 to 2018
$1.3M
NIGMS NIH HHS R01 GM110577NIGMS NIH HHS R35 GM136431
6 · The paper itself

Abstract

Amyloid fibril formation of α-synuclein (αS) is associated with multiple neurodegenerative diseases, including Parkinson's disease (PD). Growing evidence suggests that progression of PD is linked to cell-to-cell propagation of αS fibrils, which leads to seeding of endogenous intrinsically disordered monomer via templated elongation and secondary nucleation. A molecular understanding of the seeding mechanism and driving interactions is crucial to inhibit progression of amyloid formation. Here, using relaxation-based solution NMR experiments designed to probe large complexes, we probe weak interactions of intrinsically disordered acetylated-αS (Ac-αS) monomers with seeding-competent Ac-αS fibrils and seeding-incompetent off-pathway oligomers to identify Ac-αS monomer residues at the binding interface. Under conditions that favor fibril elongation, we determine that the first 11 N-terminal residues on the monomer form a common binding site for both fibrils and off-pathway oligomers. Additionally, the presence of off-pathway oligomers within a fibril seeding environment suppresses seeded amyloid formation, as observed through thioflavin-T fluorescence experiments. This highlights that off-pathway αS oligomers can act as an auto-inhibitor against αS fibril elongation. Based on these data taken together with previous results, we propose a model in which Ac-αS monomer recruitment to the fibril is driven by interactions between the intrinsically disordered monomer N terminus and the intrinsically disordered flanking regions (IDR) on the fibril surface. We suggest that this monomer recruitment may play a role in the elongation of amyloid fibrils and highlight the potential of the IDRs of the fibril as important therapeutic targets against seeded amyloid formation.

Indexed as

alpha-SynucleinAmyloidBenzothiazolesBinding SitesHumansIntrinsically Disordered ProteinsMagnetic Resonance ImagingMagnetic Resonance SpectroscopyNuclear Magnetic Resonance, BiomolecularParkinson Diseasealpha-SynucleinAmyloidBenzothiazolesIntrinsically Disordered Proteinsthioflavin Taggregation inhibitionamyloid formationamyloid seedingIDP–IDR interactionsParkinson’s disease

Identifiers

PMID33903234
PMCPMC8106326
OpenAlexW3049273506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.